Search enhanced by Google
Marc A. Dall'Era, M.D.
Vice Chair, Department of Urologic Surgery
Professor
To see if Marc A. Dall'Era is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Department
Locations and Contact
Lawrence J. Ellison Ambulatory Care Center
Lawrence J. Ellison Ambulatory Care Center
4860 Y St.
Sacramento, CA 95817
Phone: 916-734-2222
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Physician Referrals
Philosophy of Care
Throughout his career, Dr. Dall'Era has remained committed to providing his patients with the highest quality of care. He believes in taking a patient-centered approach, which means that he listens carefully to his patients' concerns, values their input, and works with them to develop a personalized treatment plan that meets their unique needs.
For Dr. Dall'Era, urologic surgery is not just about fixing problems or performing procedures; it's about improving patients' overall quality of life. He understands that many urological conditions can be stressful and embarrassing, and he works hard to create a safe and welcoming environment where his patients feel comfortable discussing their symptoms and concerns.
Clinical Interests
Dr. Dall’Era specializes in the management of malignant disease of the urinary tract.
The specialty care Dr. Dall’Era offers includes:
- Multi-disciplinary and comprehensive care of patients with urologic malignancy
- Tran/sperineal prostate biopsy
- High intensity focused ultrasound (HIFU) for prostate cancer
- Multi-parametric MRI/US fusion targeted prostate biopsy
- Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
- Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy partial and radical nephrectomy
- Radical cystectomy and neobladder creation
- Advanced genomics testing of urologic cancers
Research/Academic Interests
Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is a principal investigator on several clinical trials including for men with high risk prostate cancer and for focal therapy of early stage disease.
Division
Urology
Center/Program Affiliation
Undergraduate School
B.S., UC Davis, Davis CA 1995
Medical School
M.D., UC Davis, Davis CA 2000
Internship
General Surgery, University of Washington, Seattle WA 2000-2001
Residency
Urology, University of Washington, Seattle WA 2001-2005
Fellowship
Oncology, UC San Francisco, San Francisco CA 2006-2008
Societe Internationale D'Urologie Outstanding Webcast Award, 2020
UC Davis Health Clinician Health adn Wellbeing Excellence Award, 2020
UC Davis Comprehensive Cancer Center Clinical Trials Top Accrual Award, 2018
To view a detailed list of Dr. Dall'Era's publications, please click here.
Dall'Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):1-6. doi:10.1038/pcan.2016.51. Epub 2016 Nov 1. PMID:27801900.
Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN Jr. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb;35(2):277-283. doi:10.1007/s00345-016-1870-y. Epub 2016 Jun 15. PMID:27306686.
Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder Cancer. 2016 Oct 27;2(4):441-448. doi:10.3233/BLC-160071. PMID:28035325.
Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21;27(42):425103. doi:10.1088/0957-4484/27/42/425103. Epub 2016 Sep 19. PMID:27640312.
Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Jun 15;122(12):1897-904. doi:10.1002/cncr.29927. Epub 2016 Mar 28. PMID:27019001.
Pugashetti, N, Chandrasekar,T, Lurvey, R, Durbin-Johnson, B, Dall'Era, M, de Vere White, R, Evans, C, Yap, S. Perioperative Outcomes Following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement? Urology Practice J. 2016;3:364-370. doi:10.1016/j.urpr.2015.09.004.
Dall'Era MA, Davies BJ. Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance. Eur Urol Focus. 2015 Sep;1(2):208-209. doi:10.1016/j.euf.2015.07.001. Epub 2015 Jul 15. PMID:28723436.
Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. Urology Practice. 2015 Nov;2:343-348. doi:10.1016/j.urpr.2015.02.007.
Yuh L, Dall’Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. Urology Practice. 2015 Jul 1;2(4):154-159. doi:10.1016/j.urpr.2014.11.004.
Pugashetti N, Yap SA, Lara PN Jr, Gandour-Edwards R, Dall'Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E204-7. doi:10.5489/cuaj.2447. PMID:26085880.